Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial.

Meier JJ, Rosenstock J, Hincelin-Méry A, Roy-Duval C, Delfolie A, Coester HV, Menge BA, Forst T, Kapitza C

Diabetes care17 Apr 2015Cited by 214 (Europe PMC)

PMID25887358DOI10.2337/dc14-1984PepBankPUB-25887358

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin glargine, liraglutide 1.2 mg reduced the postprandial glucose AUC less than lixisenatide 20 µg (P < 0.001).
In plain wordsIn adults with type 2 diabetes on insulin glargine, liraglutide 1.2 mg lowered after-meal glucose less than lixisenatide.
Peptide
Liraglutide
Outcome
IncreasePostprandial plasma glucose AUC change, liraglutide 1.2 mg vs lixisenatide
Study
n: not reported in source
Comparator
Lixisenatide 20 µg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · 8 weeksAs given in this study (human).
Measurements
Treatment difference lixisenatide minus liraglutide
−6 h*mmol/L
vs liraglutide 1.2 mg
Source sentences
Summary
Lixisenatide 20 µg achieved greater reductions of AUC PPG0030-0430 h compared with liraglutide (marginal mean [95% one-sided CI] treatment difference, -6.0 [-7.8] h ⋅ mmol/L [-108.3 (-140.0) h ⋅ mg/dL] vs. liraglutide 1.2 mg and -4.6 [-6.3] h ⋅ mmol/L [-83.0 (-114.2) h ⋅ mg/dL] vs. liraglutide 1.8 m…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change from baseline to week 8 in incremental area under the postprandial plasma glucose curve for 4 h after a standardized solid breakfast (AUC PPG0030-0430 h).
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735801
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin glargine, liraglutide 1.8 mg reduced the postprandial glucose AUC less than lixisenatide 20 µg (P < 0.001).
In plain wordsIn adults with type 2 diabetes on insulin glargine, liraglutide 1.8 mg lowered after-meal glucose less than lixisenatide.
Peptide
Liraglutide
Outcome
IncreasePostprandial plasma glucose AUC change, liraglutide 1.8 mg vs lixisenatide
Study
n: not reported in source
Comparator
Lixisenatide 20 µg
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 8 weeksAs given in this study (human).
Measurements
Treatment difference lixisenatide minus liraglutide
−4.6 h*mmol/L
vs liraglutide 1.8 mg
Source sentences
Summary
Lixisenatide 20 µg achieved greater reductions of AUC PPG0030-0430 h compared with liraglutide (marginal mean [95% one-sided CI] treatment difference, -6.0 [-7.8] h ⋅ mmol/L [-108.3 (-140.0) h ⋅ mg/dL] vs. liraglutide 1.2 mg and -4.6 [-6.3] h ⋅ mmol/L [-83.0 (-114.2) h ⋅ mg/dL] vs. liraglutide 1.8 m…
2 context sentences(design, population, supporting numbers)
Summary · context
The primary end point was change from baseline to week 8 in incremental area under the postprandial plasma glucose curve for 4 h after a standardized solid breakfast (AUC PPG0030-0430 h).
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735802
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on insulin glargine, lixisenatide reduced postprandial glucose AUC more than liraglutide 1.2 mg: difference -6.0 h ⋅ mmol/L (P < 0.001).
In plain wordsIn patients with diabetes on insulin glargine, lixisenatide reduced post-meal glucose exposure more than the lower liraglutide dose.
Peptide
Lixisenatide
Outcome
DecreasePostprandial glucose AUC
Study
n: not reported in source
Comparator
Liraglutide 1.2 mg once daily
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Measurements
Treatment difference
−6 h ⋅ mmol/L
versus liraglutide 1.2 mg
One-sided 95% CI bound
−7.8 h ⋅ mmol/L
versus liraglutide 1.2 mg
Treatment difference
−108.3 h ⋅ mg/dL
versus liraglutide 1.2 mg
One-sided 95% CI bound
−140 h ⋅ mg/dL
versus liraglutide 1.2 mg
P value
< 0.001 unitless
AUC PPG0030-0430 h, lixisenatide vs liraglutide 1.2 mg
Source sentences
Summary
Lixisenatide 20 µg achieved greater reductions of AUC PPG0030-0430 h compared with liraglutide (marginal mean [95% one-sided CI] treatment difference, -6.0 [-7.8] h ⋅ mmol/L [-108.3 (-140.0) h ⋅ mg/dL] vs. liraglutide 1.2 mg and -4.6 [-6.3] h ⋅ mmol/L [-83.0 (-114.2) h ⋅ mg/dL] vs. liraglutide 1.8 m…
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735811
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on insulin glargine, lixisenatide reduced postprandial glucose AUC more than liraglutide 1.8 mg: difference -4.6 h ⋅ mmol/L (P < 0.001).
In plain wordsIn patients with diabetes on insulin glargine, lixisenatide reduced post-meal glucose exposure more than the higher liraglutide dose.
Peptide
Lixisenatide
Outcome
DecreasePostprandial glucose AUC
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg once daily
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Measurements
Treatment difference
−4.6 h ⋅ mmol/L
versus liraglutide 1.8 mg
One-sided 95% CI bound
−6.3 h ⋅ mmol/L
versus liraglutide 1.8 mg
Treatment difference
−83 h ⋅ mg/dL
versus liraglutide 1.8 mg
One-sided 95% CI bound
−114.2 h ⋅ mg/dL
versus liraglutide 1.8 mg
P value
< 0.001 unitless
AUC PPG0030-0430 h, lixisenatide vs liraglutide 1.8 mg
Source sentences
Summary
Lixisenatide 20 µg achieved greater reductions of AUC PPG0030-0430 h compared with liraglutide (marginal mean [95% one-sided CI] treatment difference, -6.0 [-7.8] h ⋅ mmol/L [-108.3 (-140.0) h ⋅ mg/dL] vs. liraglutide 1.2 mg and -4.6 [-6.3] h ⋅ mmol/L [-83.0 (-114.2) h ⋅ mg/dL] vs. liraglutide 1.8 m…
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735812
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin glargine, fasting plasma glucose was unchanged in all treatment arms, liraglutide arms included.
In plain wordsIn adults with type 2 diabetes on insulin glargine, fasting glucose did not change in any treatment arm, including liraglutide.
Peptide
Liraglutide
Outcome
No significant changeFasting plasma glucose
Study
n = 142
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 and 1.8 mg once daily · 8 weeksAs given in this study (human).
Source sentences
Summary
FPG was unchanged in all treatment arms.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735804
06HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin glargine, both liraglutide doses raised 24-h heart rate more than lixisenatide did (P < 0.001).
In plain wordsIn adults with type 2 diabetes on insulin glargine, liraglutide raised heart rate more than lixisenatide did.
Peptide
Liraglutide
Outcome
Increase24-h heart rate change
Study
n = 142
Comparator
Lixisenatide 20 µg
Outcome group
Adverse events · Cardiovascular
Studied dose
1.2 and 1.8 mg once daily · 8 weeksAs given in this study (human).
Measurements
24-h heart rate increase
9 bpm
liraglutide 1.2 and 1.8 mg
24-h heart rate increase
3 bpm
lixisenatide
Source sentences
Summary
At week 8, both liraglutide doses increased marginal mean ± SE 24-h heart rate from baseline by 9 ± 1 bpm vs. 3 ± 1 bpm with lixisenatide (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735807
07HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on insulin glargine, symptomatic hypoglycemia occurred more often with lixisenatide than liraglutide; comparator doses were not separated.
In plain wordsIn patients with diabetes on insulin glargine, symptomatic low blood sugar occurred more often with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
IncreaseSymptomatic hypoglycemia
Study
n = 142
Comparator
Liraglutide
Outcome group
Adverse events · Metabolic and weight
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Source sentences
Summary
Occurrence of symptomatic hypoglycemia was higher with lixisenatide; gastrointestinal AEs were more common with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Summary · context
In total, 142 patients were randomized and treated.
Report a problemFND-2588735819
08HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on insulin glargine, gastrointestinal adverse events occurred less often with lixisenatide than liraglutide; comparator doses were not separated.
In plain wordsIn patients with diabetes on insulin glargine, gastrointestinal side effects occurred less often with lixisenatide than liraglutide.
Peptide
Lixisenatide
Outcome
DecreaseGastrointestinal adverse events
Study
n = 142
Comparator
Liraglutide
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Source sentences
Summary
Occurrence of symptomatic hypoglycemia was higher with lixisenatide; gastrointestinal AEs were more common with liraglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Summary · context
In total, 142 patients were randomized and treated.
Report a problemFND-2588735820
09HumanRandomized controlled trialMechanism
In adults with type 2 diabetes on insulin glargine, gastric emptying was delayed less with liraglutide 1.2 and 1.8 mg than with lixisenatide (P < 0.001).
In plain wordsIn adults with type 2 diabetes on insulin glargine, liraglutide slowed stomach emptying less than lixisenatide did.
Peptide
Liraglutide
Outcome
DecreaseGastric emptying
Study
n: not reported in source
Comparator
Lixisenatide 20 µg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 and 1.8 mg once daily · 8 weeksAs given in this study (human).
Source sentences
Summary
and gastric emptying was delayed to a greater extent than with liraglutide 1.2 and 1.8 mg (P < 0.001 for treatment comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735803
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin glargine, mean HbA1c at week 8 with liraglutide 1.2 mg was 6.1 ± 0.3%.
In plain wordsIn adults with type 2 diabetes on insulin glargine, average HbA1c after 8 weeks of liraglutide 1.2 mg was 6.1%.
Peptide
Liraglutide
Outcome
Not applicableHbA1c at week 8, liraglutide 1.2 mg
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg once daily · 8 weeksAs given in this study (human).
Measurements
HbA1c at week 8
6.1%
liraglutide 1.2 mg
Source sentences
Summary
At week 8, mean ± SD HbA1c was 6.2 ± 0.4% (44 ± 5 mmol/mol), 6.1 ± 0.3% (44 ± 4 mmol/mol), and 6.1 ± 0.3% (44 ± 4 mmol/mol) for lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735805
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes on insulin glargine, mean HbA1c at week 8 with liraglutide 1.8 mg was 6.1 ± 0.3%.
In plain wordsIn adults with type 2 diabetes on insulin glargine, average HbA1c after 8 weeks of liraglutide 1.8 mg was 6.1%.
Peptide
Liraglutide
Outcome
Not applicableHbA1c at week 8, liraglutide 1.8 mg
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg once daily · 8 weeksAs given in this study (human).
Measurements
HbA1c at week 8
6.1%
liraglutide 1.8 mg
Source sentences
Summary
At week 8, mean ± SD HbA1c was 6.2 ± 0.4% (44 ± 5 mmol/mol), 6.1 ± 0.3% (44 ± 4 mmol/mol), and 6.1 ± 0.3% (44 ± 4 mmol/mol) for lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735806
12HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin glargine, symptomatic hypoglycemia occurred less often with liraglutide than with lixisenatide.
In plain wordsIn adults with type 2 diabetes on insulin glargine, low blood sugar with symptoms was less common with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
DecreaseSymptomatic hypoglycemia
Study
n: not reported in source
Comparator
Lixisenatide 20 µg
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.2 and 1.8 mg once daily · 8 weeksAs given in this study (human).
Source sentences
Summary
Occurrence of symptomatic hypoglycemia was higher with lixisenatide
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735808
13HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin glargine, gastrointestinal adverse events were more common with liraglutide than with lixisenatide.
In plain wordsIn adults with type 2 diabetes on insulin glargine, stomach and gut side effects were more common with liraglutide than with lixisenatide.
Peptide
Liraglutide
Outcome
IncreaseGastrointestinal adverse events
Study
n: not reported in source
Comparator
Lixisenatide 20 µg
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
1.2 and 1.8 mg once daily · 8 weeksAs given in this study (human).
Source sentences
Summary
gastrointestinal AEs were more common with liraglutide.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735809
14HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes on insulin glargine, lipase levels rose significantly from baseline with liraglutide 1.2 and 1.8 mg.
In plain wordsIn adults with type 2 diabetes on insulin glargine, liraglutide raised lipase, a pancreas enzyme, above starting levels.
Peptide
Liraglutide
Outcome
IncreaseLipase level change
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.2 and 1.8 mg once daily · 8 weeksAs given in this study (human).
Measurements
Lipase increase
21 IU/L
liraglutide 1.2 and 1.8 mg
Source sentences
Summary
Lipase levels were significantly increased from baseline with liraglutide 1.2 and 1.8 mg (marginal mean ± SE increase 21 ± 7 IU/L for both; P < 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735810
15HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on insulin glargine, lixisenatide delayed gastric emptying more than liraglutide 1.2 mg (P < 0.001).
In plain wordsIn patients with diabetes on insulin glargine, lixisenatide delayed stomach emptying more than the lower liraglutide dose.
Peptide
Lixisenatide
Outcome
IncreaseGastric emptying delay
Study
n: not reported in source
Comparator
Liraglutide 1.2 mg once daily
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Measurements
P value
< 0.001 unitless
gastric emptying delay, lixisenatide vs liraglutide 1.2 mg
Source sentences
Summary
and gastric emptying was delayed to a greater extent than with liraglutide 1.2 and 1.8 mg (P < 0.001 for treatment comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735813
16HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes on insulin glargine, lixisenatide delayed gastric emptying more than liraglutide 1.8 mg (P < 0.001).
In plain wordsIn patients with diabetes on insulin glargine, lixisenatide delayed stomach emptying more than the higher liraglutide dose.
Peptide
Lixisenatide
Outcome
IncreaseGastric emptying delay
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Gastrointestinal function · Gastrointestinal
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Measurements
P value
< 0.001 unitless
gastric emptying delay, lixisenatide vs liraglutide 1.8 mg
Source sentences
Summary
and gastric emptying was delayed to a greater extent than with liraglutide 1.2 and 1.8 mg (P < 0.001 for treatment comparisons).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735814
17HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on insulin glargine, heart rate increased 3 ± 1 bpm with lixisenatide versus 9 ± 1 bpm with liraglutide 1.2 mg (P < 0.001).
In plain wordsIn patients with diabetes on insulin glargine, heart rate increased less with lixisenatide than the lower liraglutide dose.
Peptide
Lixisenatide
Outcome
Decrease24-hour heart rate change
Study
n: not reported in source
Comparator
Liraglutide 1.2 mg once daily
Outcome group
Adverse events · Cardiovascular
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Measurements
24-h heart rate change from baseline (marginal mean)
3 bpm
lixisenatide 20 µg, week 8
SE of 24-h heart rate change
1 bpm
lixisenatide 20 µg, week 8
24-h heart rate change from baseline (marginal mean)
9 bpm
liraglutide 1.2 mg, week 8
SE of 24-h heart rate change
1 bpm
liraglutide 1.2 mg, week 8
P value
< 0.001 unitless
24-h heart rate change, lixisenatide vs liraglutide
Source sentences
Summary
At week 8, both liraglutide doses increased marginal mean ± SE 24-h heart rate from baseline by 9 ± 1 bpm vs. 3 ± 1 bpm with lixisenatide (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735817
18HumanRandomized controlled trialSafety outcome
In patients with type 2 diabetes on insulin glargine, heart rate increased 3 ± 1 bpm with lixisenatide versus 9 ± 1 bpm with liraglutide 1.8 mg (P < 0.001).
In plain wordsIn patients with diabetes on insulin glargine, heart rate increased less with lixisenatide than the higher liraglutide dose.
Peptide
Lixisenatide
Outcome
Decrease24-hour heart rate change
Study
n: not reported in source
Comparator
Liraglutide 1.8 mg once daily
Outcome group
Adverse events · Cardiovascular
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Measurements
24-h heart rate change from baseline (marginal mean)
3 bpm
lixisenatide 20 µg, week 8
SE of 24-h heart rate change
1 bpm
lixisenatide 20 µg, week 8
24-h heart rate change from baseline (marginal mean)
9 bpm
liraglutide 1.8 mg, week 8
SE of 24-h heart rate change
1 bpm
liraglutide 1.8 mg, week 8
P value
< 0.001 unitless
24-h heart rate change, lixisenatide vs liraglutide
Source sentences
Summary
At week 8, both liraglutide doses increased marginal mean ± SE 24-h heart rate from baseline by 9 ± 1 bpm vs. 3 ± 1 bpm with lixisenatide (P < 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735818
19HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes on insulin glargine, fasting plasma glucose remained unchanged in all arms, including lixisenatide.
In plain wordsIn patients with diabetes on insulin glargine, fasting glucose remained unchanged in all treatment groups, including lixisenatide.
Peptide
Lixisenatide
Outcome
No significant changeFasting plasma glucose
Study
n: not reported in source
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Source sentences
Summary
FPG was unchanged in all treatment arms.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735815
20HumanNon-randomized trialEfficacy outcome
In patients with type 2 diabetes on insulin glargine, mean HbA1c with lixisenatide was 6.2 ± 0.4% (44 ± 5 mmol/mol) at week 8.
In plain wordsIn patients with diabetes on insulin glargine, the study reported HbA1c during lixisenatide treatment at the final assessment.
Peptide
Lixisenatide
Outcome
Not applicableHbA1c at week 8
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
20 µg once daily · 8 weeksAs given in this study (human).
Measurements
Mean HbA1c
6.2%
lixisenatide 20 µg, week 8
SD of HbA1c
0.4%
lixisenatide 20 µg, week 8
Mean HbA1c
44 mmol/mol
lixisenatide 20 µg, week 8
SD of HbA1c
5 mmol/mol
lixisenatide 20 µg, week 8
Source sentences
Summary
At week 8, mean ± SD HbA1c was 6.2 ± 0.4% (44 ± 5 mmol/mol), 6.1 ± 0.3% (44 ± 4 mmol/mol), and 6.1 ± 0.3% (44 ± 4 mmol/mol) for lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
This was a multicenter, randomized, open-label, three-arm trial comparing lixisenatide 20 µg and liraglutide 1.2 and 1.8 mg once daily for 8 weeks in combination with insulin glargine after optimized titration.
Report a problemFND-2588735816

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT01596504

Pharmacodynamic Effects of Lixisenatide Compared to Liraglutide in Patients With Type 2 Diabetes Not Adequately Controlled With Insulin Glargine With or Without Metformin

Sanofin = 142May 2012 to Jul 2013

Type 2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 14 Oct 2016

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 3
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.